{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:37:33Z","timestamp":1760297853346},"reference-count":64,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T00:00:00Z","timestamp":1187827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2008,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mantle cell lymphoma (MCL), an aggressive non\u2010Hodgkin's lymphoma characterized by t(11; 14)(q13; q32) chromosomal translocation and overexpression of cyclin D1, has the worst prognosis among all lymphomas. Recent advances in biology, genetics, and immunology have supported the development of immunotherapy in MCL. Rituximab monotherapy in MCL has limited activity. It is more effective when used in combination with chemotherapy such as R\u2010CHOP, R\u2010hyperCVAD\/MTX\u2010Ara\u2010C, or R\u2010FCM as front\u2010line or salvage therapy for mantle cell lymphoma. Maintenance with Rituximab was shown to prolong response duration. Although most results have suggested that combining autologous stem cell transplantation with Rituximab may lead to durable remission, the sample size was not sufficient to declare survival benefit. Anti\u2010CD20 radioimmunoconjugates (RICs) <jats:sup>90<\/jats:sup>Yttrium\u2010ibritumomab tiuxetan and <jats:sup>131<\/jats:sup>Iodine\u2010tositumomab have been used in mantle cell lymphoma even when patients are relatively resistant to Rituximab\u2010based therapy. Allogeneic stem cell transplantation is a treatment modality in advanced or relapsed MCL, particularly using reduced\u2010intensity conditioning. MCL may have high response rates and sustained remissions after donor lymphocyte infusion. Dendritic cells (DCs) fused with MCL cells for immunostimulation have preliminarily shown anti\u2010lymphoma effects as well. Idiotype vaccination in MCL patients following Rituximab\u2010containing chemotherapy induced tumor\u2010specific T\u2010cell immunity in the absence of B cells. Other immunotherapy, such as the combination of thalidomide with Rituximab, has shown substantial antitumor activity. A Phase I\/II study is ongoing to determine the maximum tolerated dose (MTD) and the efficacy of lenalidomide in combination with Rituximab for relapsed\/refractory MCL. This review summarizes the latest and exciting advances in MCL. Am. J. Hematol., 2008. \u00a9 2007 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.21036","type":"journal-article","created":{"date-parts":[[2007,8,25]],"date-time":"2007-08-25T01:49:18Z","timestamp":1188006558000},"page":"144-149","source":"Crossref","is-referenced-by-count":18,"title":["Immunotherapy in mantle cell lymphoma: Anti\u2010CD20\u2010based therapy and beyond"],"prefix":"10.1002","volume":"83","author":[{"given":"Yuhong","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kay","family":"Delasalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Larry","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Yi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,23]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00028-X"},{"key":"e_1_2_1_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.050"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.07.9665"},{"key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"608a","DOI":"10.1182\/blood.V104.11.608.608","article-title":"A Phase II study of bortezomib in patients with mantle cell lymphoma","volume":"104","author":"Belch A","year":"2004","journal-title":"Blood"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"2753a","DOI":"10.1182\/blood.V108.11.2753.2753","article-title":"Marked activity of bortezomib, rituximab, and dexamethasone (BORID) in heavily pretreated patients with mantle cell lymphoma","volume":"108","author":"Drach J","year":"2006","journal-title":"Blood"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.466"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.13.466"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.164"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008309405678"},{"key":"e_1_2_1_11_2","first-page":"1927","article-title":"Rituximab (anti\u2010CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study","volume":"92","author":"Coiffier B","year":"1998","journal-title":"Blood"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1999.tb01725.x"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.133"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.1825"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-04-1323"},{"key":"e_1_2_1_16_2","doi-asserted-by":"crossref","first-page":"7502a","DOI":"10.1200\/jco.2006.24.18_suppl.7502","article-title":"Rituximab maintenance improves progression\u2010free and overall survival rates after combined immuno\u2010chemotherapy (R\u2010FCM) in patients with relapsed follicular and mantle cell lymphoma: Final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)","volume":"24","author":"Dreyling M","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_17_2","doi-asserted-by":"crossref","first-page":"2746a","DOI":"10.1182\/blood.V108.11.2746.2746","article-title":"Phase II study of rituximab and cladribine (2\u2010CDA) in newly diagnosed mantle cell lymphoma (MCL)","volume":"108","author":"Inwards DJ","year":"2006","journal-title":"Blood"},{"key":"e_1_2_1_18_2","doi-asserted-by":"crossref","first-page":"7528a","DOI":"10.1200\/jco.2006.24.18_suppl.7528","article-title":"A phase II, multicenter study of bendamustine HCL plus rituximab in relapsed indolent B\u2010cell and mantle\u2010cell non\u2010Hodgkin's lymphoma (NHL)","volume":"24","author":"William ME","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.08.100"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05777.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"7511a","DOI":"10.1200\/jco.2006.24.18_suppl.7511","article-title":"Mantle cell lymphoma (MCL): Induction therapy with HyperCVAD\/High\u2010dose methotrexate and cytarabine (M\u2010C) (\u00b1 rituximab) improves results of autologous stem cell transplant in first remission","volume":"24","author":"Vose J","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703925"},{"key":"e_1_2_1_23_2","first-page":"425","article-title":"Rituximab and DHAP followed by intensive therapy with autologous stem\u2010cell transplantation as first\u2010line therapy for mantle cell lymphoma","volume":"91","author":"de Guibert S","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21313"},{"key":"e_1_2_1_25_2","doi-asserted-by":"crossref","first-page":"7555a","DOI":"10.1200\/jco.2006.24.18_suppl.7555","article-title":"Impact of rituximab on outcome of autologous transplantation for mantle cell lymphoma","volume":"24","author":"Naing A","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_26_2","doi-asserted-by":"crossref","first-page":"2734a","DOI":"10.1182\/blood.V108.11.2734.2734","article-title":"First report of the HOVON 45: A phase II study with rituximab, high dose Ara\u2010C and autologous stem cell transplantation in the primary treatment of mantle cell lymphoma","volume":"108","author":"Van't Veer MB","year":"2006","journal-title":"Blood"},{"key":"e_1_2_1_27_2","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1182\/blood.V108.11.3045.3045","article-title":"Frontline high dose sequential chemotherapy with rituximab (R\u2010HDS) and autologous stem cell transplantation induces high rates of complete response and prolonges survival in mantle cell lymphoma (MCL)","volume":"108","author":"Cortelazzo S","year":"2006","journal-title":"Blood"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1703296"},{"key":"e_1_2_1_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh090"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.13"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1053\/sonc.2002.30143"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdh425"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190500052461"},{"key":"e_1_2_1_34_2","doi-asserted-by":"crossref","first-page":"3051a","DOI":"10.1182\/blood.V108.11.3051.3051","article-title":"Autologous stem cell transplant with a rituximab pruge and maintenance vs. standard chemotherapy for mantle cell lymphoma: Extended follow\u2010up of a matched pair analysis","volume":"108","author":"Hicks L","year":"2006","journal-title":"Blood"},{"key":"e_1_2_1_35_2","doi-asserted-by":"crossref","first-page":"2714a","DOI":"10.1182\/blood.V108.11.2714.2714","article-title":"Phase II study of Yttrium 90 (90Y) ibritumomab tiuxetan (Zevalin\u00ae) in patients with relapsed and refractory mantle cell lymphoma (MCL)","volume":"108","author":"Wang M","year":"2006","journal-title":"Blood"},{"key":"e_1_2_1_36_2","doi-asserted-by":"crossref","first-page":"7533a","DOI":"10.1200\/jco.2006.24.18_suppl.7533","article-title":"Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: Results of two phase II trials of European MCL Network and the PLRG","volume":"24","author":"Weigert O","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_37_2","doi-asserted-by":"crossref","first-page":"7503a","DOI":"10.1200\/jco.2006.24.18_suppl.7503","article-title":"Phase II study of rituximab+CHOP followed by 90Y\u2010ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group Study (E1499)","volume":"24","author":"Smith MR","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_38_2","doi-asserted-by":"crossref","first-page":"2747a","DOI":"10.1182\/blood.V108.11.2747.2747","article-title":"90Y\u2010 Zevalin\u00ae (90Y\u2010Ibritumomab Tiuxetan) radioimmunotherapy (RIT) consolidation for FCM induction chemotherapy in mantle cell lymphoma (MCL) patients: Results from the PLRG upon completed enrollment","volume":"108","author":"Jurczak W","year":"2006","journal-title":"Blood"},{"key":"e_1_2_1_39_2","first-page":"7560a","article-title":"Sequential radioimmunotherapy with tositumomab\/Iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions","volume":"24","author":"Zelenetz AD","year":"2006","journal-title":"Clin Oncol"},{"key":"e_1_2_1_40_2","doi-asserted-by":"crossref","first-page":"2452a","DOI":"10.1182\/blood.V106.11.2452.2452","article-title":"Activity of Yttrium 90 (90Y) Ibritumomab Tiuxetan (Zevalin) in 22 patients with relapsed and refractory mantle cell lymphoma (MCL)","volume":"106","author":"Youngs A","year":"2005","journal-title":"Blood"},{"key":"e_1_2_1_41_2","doi-asserted-by":"crossref","first-page":"681a","DOI":"10.1182\/blood.V106.11.681.681","article-title":"New transplant strategies utilizing radioimmunotherapy (RIT) based regimens to reduce relapse in high risk mantle cell lymphoma (MCL)","volume":"106","author":"Krishnan A","year":"2005","journal-title":"Blood"},{"key":"e_1_2_1_42_2","doi-asserted-by":"crossref","first-page":"6504a","DOI":"10.1200\/jco.2004.22.90140.6504","article-title":"High\u2010dose radioimmunotherapy with yttrium 90 (90Y) ibritumomab tiuxetan with high\u2010dose etoposide (VP\u201016) and cyclophosphamide (CY) followed by autologous hematopoietic cell transplant (AHCT) for poor\u2010risk or relapsed B\u2010cell non\u2010Hodgkin's lymphoma (NHL): Update of a phase I\/II trial","volume":"22","author":"Nademanee A","year":"2004","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_43_2","first-page":"7587a","article-title":"High dose 90Yttrium ibritumomab tiuxetan with PBSC support in refractory\u2010resistant NHL patients: preliminary results of a phase I\/II study","volume":"24","author":"Vanazzi A","year":"2006","journal-title":"Clin Oncol"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.9.3158"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001622-200403000-00004"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2275"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1105"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.05.501"},{"key":"e_1_2_1_49_2","doi-asserted-by":"crossref","first-page":"3123a","DOI":"10.1182\/blood.V108.11.3123.3123","article-title":"Matched unrelated donor stem cell transplantation for relapsed or refractory mantle cell lymphoma. A retrospective analysis from the EBMT Lymphoma Working Party","volume":"108","author":"Avivi I","year":"2006","journal-title":"Blood"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705074"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2425"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/13928"},{"issue":"1","key":"e_1_2_1_53_2","first-page":"341a","article-title":"A phase II study demonstrating recombinant idiotype vaccine elicits specific anti\u2010idiotype immune responses in aggressive non\u2010Hodgkin's lymphoma","volume":"98","author":"Timmerman JM","year":"2001","journal-title":"Blood"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2004.11.036"},{"key":"e_1_2_1_55_2","first-page":"3345a","article-title":"Early and robust immune responses to immune responses to idiotype (Id) vaccination occur in mantle cell lymphoma (MCL) and indolent lymphoma patients following autologous stem cell transplantation (ASCT)","volume":"102","author":"Holman P","year":"2003","journal-title":"Blood"},{"key":"e_1_2_1_56_2","first-page":"105a","article-title":"Recombinant idiotype\u2010KLH vaccination (MyVaxTM) following CHOP chemotherapy in mantle cell lymphoma","volume":"102","author":"Leonard JP","year":"2003","journal-title":"Blood"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1290"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.5.1517"},{"key":"e_1_2_1_59_2","first-page":"1337","article-title":"Dendritic cell\u2010based therapy for mantle cell lymphoma","volume":"28","author":"Munger CM","year":"2006","journal-title":"Int J Oncol"},{"key":"e_1_2_1_60_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403058"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-03-1091"},{"key":"e_1_2_1_62_2","doi-asserted-by":"crossref","first-page":"8030a","DOI":"10.1200\/jco.2007.25.18_suppl.8030","article-title":"A phase I\/II study of lenalidomide (Len) in combination with rituximab (R) in relapsed\/refractory mantle cell lymphoma (MCL) with early evidence of efficacy","volume":"25","author":"Wang M","year":"2007","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_63_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-005-0063-4"},{"key":"e_1_2_1_64_2","doi-asserted-by":"crossref","first-page":"7534a","DOI":"10.1200\/jco.2006.24.18_suppl.7534","article-title":"A humanized antibody against CD40 (SGN\u201040) is well tolerated and active in non\u2010Hodgkin's lymphoma (NHL): Results of a Phase I study","volume":"24","author":"Forero\u2010Torres A","year":"2006","journal-title":"J Clin Oncol"},{"key":"e_1_2_1_65_2","first-page":"898a","article-title":"Safety and efficacy of heat shock protein\u2010peptide96 complex (HSPPC\u201096) vaccine therapy in patients with relapsed or previously untreated low\u2010grade non\u2010Hodgkin's lymphoma","volume":"102","author":"Younes A","year":"2003","journal-title":"Blood"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.21036","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.21036","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T16:39:42Z","timestamp":1700066382000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.21036"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,23]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,2]]}},"alternative-id":["10.1002\/ajh.21036"],"URL":"https:\/\/doi.org\/10.1002\/ajh.21036","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,23]]}}}